About: The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas
Creator	Agarwal, Neeraj Hahn, Andrew
source	PMC
abstract	covid:5a8c3c0d9725de1d53143fb8b1ffc17252c316a2#abstract
has issue date	2020-07-04(xsd:dateTime)
bibo:doi	10.1016/j.ctarc.2020.100190
has license	no-cc
sha1sum (hex)	5a8c3c0d9725de1d53143fb8b1ffc17252c316a2
schema:url	https://doi.org/10.1016/j.ctarc.2020.100190
resource representing a document's title	The rapidly evolving treatment landscape of advanced prostate, bladder, and renal cell carcinomas
has PubMed Central identifier	PMC7334643
schema:publication	Cancer Treat Res Commun
resource representing a document's body	covid:5a8c3c0d9725de1d53143fb8b1ffc17252c316a2#body_text
is schema:about of	named entity 'carcinomas' named entity 'olaparib' named entity 'radiographic' named entity 'ORR' named entity 'phase III clinical trial' named entity 'BRCA' named entity 'objective response rate' named entity 'supportive care' named entity 'first-line treatment' named entity 'olaparib' named entity 'prostate' named entity 'ribose' named entity 'Olaparib' named entity 'rucaparib' named entity 'US Food and Drug Administration' named entity 'olaparib' named entity 'PFS' named entity 'BRCA' named entity 'mUC' named entity 'BRCA1' named entity 'metastatic urothelial carcinoma' named entity 'radium-223' named entity 'enzalutamide' named entity 'olaparib' named entity 'Bladder' named entity 'clinical studies' named entity 'ATM' named entity 'olaparib' named entity '18.5' named entity 'veliparib' named entity 'monotherapy' named entity 'clinical trials' named entity 'FDA' named entity 'rucaparib' named entity 'mUC' named entity 'coronavirus pandemic' named entity 'carcinomas' named entity 'bladder' named entity 'olaparib' named entity 'PARP inhibitors' named entity 'platinum-based chemotherapy' named entity 'phase III clinical trial' named entity 'refractory' named entity 'prostate' named entity 'platinum-based chemotherapy' named entity 'first-line treatment' named entity 'BRCA1' named entity 'rucaparib' named entity 'BRCA1/2' named entity 'PARP inhibitors' named entity 'avelumab' named entity 'Rucaparib' named entity 'PARP' named entity 'ATM' named entity 'Germline mutations' named entity 'taxane' named entity 'bladder' named entity 'platinum-based chemotherapy' named entity 'FDA' named entity 'mUC' named entity 'adenosine diphosphate' named entity 'PARP inhibitors' named entity 'homologous recombination repair' named entity 'ASCO' named entity 'rucaparib' named entity 'RCC' named entity 'phase II trial' named entity 'platinum-based chemotherapy' named entity 'COVID-19' named entity 'HRR' named entity 'genitourinary' named entity 'avelumab' named entity 'abiraterone' named entity 'chemotherapy' named entity 'bladder' named entity 'hormonal therapy' named entity 'metastatic castration-resistant prostate cancer' named entity 'control arm' named entity 'talazoparib' named entity 'BRCA2' named entity 'immune checkpoint inhibitors' named entity 'rucaparib'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software